Polynovo Limited · ASX:PNV
Polynovo — Investor Presentation (January 2020)
30 slides from Polynovo's investor presentation, Jan 20, 2020
Slide 1: PolyNovo Investor Update Hong Kong & Singapore
For personal use only PolyNovo Investor Update Hong Kong & Singapore January 2020
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo For personal use only has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or u
Slide 3: NovoSorb polymer: A unique platform technology
NovoSorb® polymer A unique platform technology For personal use only NovoSorb® • Base polymer developed by the CSIRO (Australian Government Research Organisation) with PolyNovo developing the medical devices • Unique polymer technology, Carbamate, that is programmable for re-absorbsion rate and prod
Slide 4: NovoSorb BTM fully resorbed
NovoSorb BTM fully resorbed For personal use only 4
Slide 5: When BTM is placed in a wound
When BTM is placed in a wound For personal use only NovoSorb BTM applied to debrided wound bed 1 The wound is ‘physiologically closed’, limiting contraction and risk of infection. NovoSorb BTM fully integrated 2 Full thickness tissue deposited within the foam. Once integrated, the seal is ready for
Slide 6: How does NovoSorb BTM work?
How does NovoSorb BTM work ? For personal use only The BTM foam breaks up a large wound (marcrowound) into a series of small, interconnected microwounds. The body easily heals microwounds, promoting organized regenerative healing. Normal Healing: The body’s natural Healing with BTM: The NovoSorb foa
Slide 7: Blanching & Delamination Video
Blanching & Delamination For personal use only Video 7
Slide 8: Allows for Staged Grafting
Allows for Staged Grafting For personal use only Note the maturity of this graft 7 days post- application. The mesh spaces are closed. A truly outstanding result. Pt 5 Day 31 post-NovoSorb BTM Pt 5 Day 38 post- NovoSorb BTM Page 9 9 9
Slide 9: Necrotising Fasciitis
Necrotising Fasciitis Anterior Cervical and Upper Thoracic For personal use only Three months post grafting 11
Slide 10: NovoSorb BTM over tendon
NovoSorb BTM over tendon For personal use only Degloving injury with tendons missing the paratenon. NovoSorb BTM was left on for 9 weeks before grafting. Day 316 12
Slide 11: Ultrasound video of the tendon freely gliding
For personal use only Ultrasound video of the tendon freely gliding, no adherence under the BTM/regenerated tissue Page 13 19/01/2020 13
Slide 12: Noah's Story
For personal use only Noah’s Story 14
Slide 13: Regulatory approvals
Regulatory approvals For personal use only Approved In Process Class III Medical device o South Korea ✓US FDA 510(K) o Taiwan ✓CE Certification Europe, UK, Ireland o Mexico ✓TGA Inclusion o Kuwait ✓NZ MedSafe ✓South Africa ✓India ✓Malaysia ✓Singapore ✓Israel 15
Slide 14: NovoSorb BTM current market entries
NovoSorb BTM current market entries Europe For personal use only India and Asia ⚫ CE Certification Dec ‘19 ⚫ Myovatec partner in India ⚫ UK/Irl direct entry 3 salespeople ⚫ Look to more direct market ⚫ DACH distributor PMI opportunities in Asia ⚫ Other EU markets consider direct Sweden USA Australia
Slide 15: NovoSorb BTM Commercial Revenues
NovoSorb BTM Commercial Revenues For personal use only BTM $M AUD 8.45 9.348 1.747 0.13896 FY17 FY18 FY19 FY20 H1 BTM NB: Excludes all other revenues- only BTM sales 17
Slide 16: Surgeon's Sharing
For personal use only Surgeon’s Sharing 18
Slide 17: Wide range of indications and applications
Wide range of indications and applications For personal use only 19
Slide 18: Clinical Trial update
Clinical Trial update • CE Burn trial is complete with final publication of results due by For personal use only end of March 2020 • BARDA funded Feasibility trial results will be published ~ March 2020 sites were – Wake Forest Baptist Health, Winston-Salem, – University of Tennessee Medical Centre,
Slide 19: Pipeline Development
Pipeline Development For personal use only NovoSorb BTM is currently on sale • Unique biodegradable purely synthetic • Market expansion for the use of dermal scaffolds Pipeline development – a platform technology • Hernia devices preparing for manufacturing scale up with equipment deliveries in prog
Slide 20: Production Capacity
Production Capacity For personal use only • Have run 2 shifts to build inventory • Currently hold 6 months forward inventories on a rolling forecast basis • Capacity increase through: – Centralised larger polyol reactor in combined Hernia/BTM facility (unit 1) – Centralised Foam production in dedica
Slide 21: Offices & Factory Build
Offices & Factory Build For personal use only 23
Slide 22: It takes a team
For personal use only It takes a team 24
Slide 23: New Website February 2020
New Website February 2020 For personal use only 25
Slide 24: AusBiotech Johnson & Johnson Award
AusBiotech Johnson & Johnson Award For personal use only Awarded 2019 Company of the Year by AusBiotech and Johnson & Johnson Innovation 26
Slide 25: Thank You
For personal use only Thank You 27
Slide 26: The Board
The Board PNV Mr David Williams (B.Ec (Hons), M.Ec, FAICD) For personal use only Non-executive Chairman Mr Williams was appointed as a Nonexecutive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and investment banker with a proven track record in b
Slide 27: The Board (2)
The Board (2) For personal use only Mr Bruce Rathie (B.Comm, LLB, MBA, FAIM, FAICD, FGIA) Non-executive Director Mr Rathie is an experienced Company Director with a finance and legal background. He practised as a partner in a large legal firm and acted as Senior Corporate Counsel to Bell Resources L
Slide 28: Management
Management For personal use only Mr Paul Brennan (MBA, BSc (Nursing) RN RM) Chief Executive Officer Mr Brennan was appointed Chief Executive Officer (CEO) of PolyNovo Ltd on 13 February 2015. Mr Brennan has extensive knowledge, exposure and understanding of the health system through his clinical bac
Slide 29: Management (2)
Management (2) For personal use only Dr. Tim Moore Principle Scientist completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the tit
Slide 30: For personal use only
For personal use only 32